Expert Ratings for C4 Therapeutics
Portfolio Pulse from Benzinga Insights
C4 Therapeutics (NASDAQ:CCCC) has received various analyst ratings in the last quarter, with 2 bullish, 1 somewhat bullish, and 1 indifferent. The average price target is $10.5, significantly higher than the current price of $1.47. However, this target represents a 35.38% decrease from the previous average price target of $16.25.
November 03, 2023 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
C4 Therapeutics has received mixed analyst ratings, with an average price target of $10.5, which is significantly higher than its current price. However, this target is a decrease from the previous one.
The mixed analyst ratings indicate uncertainty about the company's performance. However, the average price target being significantly higher than the current price suggests potential upside, which could positively impact the stock price. The decrease in the target from the previous one might indicate lowered expectations, but it's still higher than the current price, indicating a positive outlook.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100